Beacon Harbor Wealth Advisors Inc. Invests $5.81 Million in Krystal Biotech, Inc. (NASDAQ:KRYS)

Key Points

• Beacon Harbor Wealth Advisors Inc. purchased a new stake in Krystal Biotech, acquiring 32,235 shares valued at approximately $5.81 million, representing 0.11% ownership as of the latest SEC filing.
• Insider Suma Krishnan sold 13,435 shares for about $2 million, reducing their ownership by 0.92% after the transaction.
• Krystal Biotech reported earnings of $1.29 per share for the latest quarter, exceeding analyst expectations and generating revenues of $96.04 million, also above estimates.

Beacon Harbor Wealth Advisors Inc. purchased a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 32,235 shares of the company's stock, valued at approximately $5,812,000. Beacon Harbor Wealth Advisors Inc. owned approximately 0.11% of Krystal Biotech at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in KRYS. Crossmark Global Holdings Inc. boosted its position in shares of Krystal Biotech by 2.7% during the first quarter. Crossmark Global Holdings Inc. now owns 2,370 shares of the company's stock worth $427,000 after buying an additional 63 shares during the period. Summit Investment Advisors Inc. lifted its holdings in Krystal Biotech by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company's stock worth $407,000 after purchasing an additional 82 shares during the period. Xponance Inc. lifted its holdings in Krystal Biotech by 4.9% in the first quarter. Xponance Inc. now owns 1,873 shares of the company's stock worth $338,000 after purchasing an additional 88 shares during the period. Sound View Wealth Advisors Group LLC lifted its holdings in Krystal Biotech by 6.7% in the first quarter. Sound View Wealth Advisors Group LLC now owns 1,515 shares of the company's stock worth $273,000 after purchasing an additional 95 shares during the period. Finally, New York State Teachers Retirement System lifted its holdings in Krystal Biotech by 0.6% in the first quarter. New York State Teachers Retirement System now owns 15,979 shares of the company's stock worth $2,881,000 after purchasing an additional 100 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Trading Up 1.9%

Shares of NASDAQ KRYS traded up $2.56 during mid-day trading on Friday, reaching $138.66. The company had a trading volume of 332,066 shares, compared to its average volume of 422,365. The stock has a market cap of $4.01 billion, a PE ratio of 28.18 and a beta of 0.70. The company has a 50-day moving average price of $141.94 and a two-hundred day moving average price of $155.36. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $207.84.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.21. The business had revenue of $96.04 million for the quarter, compared to analysts' expectations of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. On average, research analysts expect that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 13,435 shares of Krystal Biotech stock in a transaction on Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. The trade was a 0.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold a total of 49,800 shares of company stock worth $7,487,943 in the last quarter. Insiders own 13.70% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on KRYS shares. HC Wainwright reaffirmed a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a report on Friday, July 25th. Guggenheim dropped their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Citigroup reissued a "neutral" rating and issued a $166.00 price objective (down previously from $176.00) on shares of Krystal Biotech in a research note on Tuesday. Chardan Capital reissued a "buy" rating and issued a $219.00 price objective on shares of Krystal Biotech in a research note on Tuesday. Finally, Bank of America dropped their price objective on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Krystal Biotech presently has an average rating of "Buy" and a consensus target price of $210.22.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).